Straits Times Index
3,384.29 +20.61 (+0.61%) Nikkei
27,509.46 +107.41 (+0.39%) Hang Seng
21,660.47 -297.89 (-1.36%) FTSE 100
7,901.80 +81.64 (+1.04%) BTC-USD
23,444.49 +19.37 (+0.08%) CMC Crypto 200
535.42 -1.43 (-0.27%)
Vertex Pharmaceuticals Incorporated (VRTX)
After hours:
| Previous close | 303.78 |
| Open | 304.56 |
| Bid | 301.02 x 1000 |
| Ask | 309.50 x 1400 |
| Day's range | 300.75 - 306.40 |
| 52-week range | 225.28 - 325.19 |
| Volume | |
| Avg. volume | 1,444,326 |
| Market cap | 77.269B |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 24.22 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
BOSTON, January 17, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call".
- Business Wire
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
BOSTON, January 04, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT.
- Business Wire
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
BOSTON, December 12, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease for the approximately 5,000 people with CF who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Vertex plans to initiate a sin
